CarmelietE. Electrophysiologic and voltage clamp analysis of the effects of Sotalol on isolated cardiac muscle and purkinje fibers. J Pharmacol Exp Ther1985; 232: 817–25.
4.
TouboulPAtallahGKrikorianGLamaudMMoleurP. Clinical electro-physiology of intravenous Sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J1984; 107: 888–95.
5.
HohnloserSHWoosleyRL. Sotalol. N Engl J Med1994; 331: 31–8.
6.
DaubertCMaboPGrasDLeclercoC. Clinical role of d-sotalol and D,L-sotalol in supraventricular arrhythmias, including pre-excitation. Eur Heart J1993; 14 (suppl H): 67–73.
7.
SinghSSainiRKDiMarcoJKlugerJGoldRChenYW. Efficacy and safety of Sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol1991; 68: 1227–30.
8.
Juul-MollerSEdvardsonNRehnqvist-AhlbergN. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation1990; 82: 1932–9.
9.
ReimoldSCCantillonCOFriedmanPLAmmanEM. Propafenone versus Sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol1993; 71: 558–63.
10.
SuttorpMJKingmaJHPeelsHOJKoomenEMTijssenJGvan HemelNM. Effectiveness of Sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol1991, 68: 1163–9.
11.
HalinenMOHuttunenMPaakkinenSTarssanenL. Comparison of Sotalol with digoxin—quinidine for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol1995; 76: 495–8.
12.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med1989; 321: 406–12.
13.
American hospital formulary service drug information. Bethesda, MD: American Society of Hospital Pharmacists, 1994: 1062–6.
